Cargando…
5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112498/ http://dx.doi.org/10.1097/01.HS9.0000928136.09596.24 |
| _version_ | 1785027634966560768 |
|---|---|
| author | van Dijk, M.J. Rab, M.A.E. van Oirschot, B.A. Bos, J.F. Derichs, C. Rijneveld, A.W. Cnossen, M.H. Nur, E. Biemond, B.J. Bartels, M. Jans, J.J.M. van Solinge, W.W. Schutgens, R.E.G. van Wijk, R. van Beers, E.J. |
| author_facet | van Dijk, M.J. Rab, M.A.E. van Oirschot, B.A. Bos, J.F. Derichs, C. Rijneveld, A.W. Cnossen, M.H. Nur, E. Biemond, B.J. Bartels, M. Jans, J.J.M. van Solinge, W.W. Schutgens, R.E.G. van Wijk, R. van Beers, E.J. |
| author_sort | van Dijk, M.J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10112498 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101124982023-04-19 5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE van Dijk, M.J. Rab, M.A.E. van Oirschot, B.A. Bos, J.F. Derichs, C. Rijneveld, A.W. Cnossen, M.H. Nur, E. Biemond, B.J. Bartels, M. Jans, J.J.M. van Solinge, W.W. Schutgens, R.E.G. van Wijk, R. van Beers, E.J. Hemasphere Oral Presentations Lippincott Williams & Wilkins 2023-04-10 /pmc/articles/PMC10112498/ http://dx.doi.org/10.1097/01.HS9.0000928136.09596.24 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Presentations van Dijk, M.J. Rab, M.A.E. van Oirschot, B.A. Bos, J.F. Derichs, C. Rijneveld, A.W. Cnossen, M.H. Nur, E. Biemond, B.J. Bartels, M. Jans, J.J.M. van Solinge, W.W. Schutgens, R.E.G. van Wijk, R. van Beers, E.J. 5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE |
| title | 5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE |
| title_full | 5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE |
| title_fullStr | 5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE |
| title_full_unstemmed | 5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE |
| title_short | 5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE |
| title_sort | 5589320 follow-up results of a phase 2 study assessing the safety and efficacy of mitapivat treatment, an oral pyruvate kinase activator, for up to 60 weeks in subjects with sickle cell disease |
| topic | Oral Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112498/ http://dx.doi.org/10.1097/01.HS9.0000928136.09596.24 |
| work_keys_str_mv | AT vandijkmj 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT rabmae 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT vanoirschotba 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT bosjf 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT derichsc 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT rijneveldaw 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT cnossenmh 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT nure 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT biemondbj 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT bartelsm 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT jansjjm 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT vansolingeww 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT schutgensreg 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT vanwijkr 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease AT vanbeersej 5589320followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease |